Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE)
Background: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 August 2016
|
| In: |
Oncology research and treatment
Year: 2016, Jahrgang: 39, Heft: 9, Pages: 539-547 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000448085 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1159/000448085 Verlag, Volltext: http://www.karger.com/Article/FullText/448085 
|
| Verfasserangaben: | Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A. Socinski, Henrik Depenbrock, Victoria Soldatenkova, Jacqueline Brown, Thomas Krause, Nick Thatcher |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1569773653 | ||
| 003 | DE-627 | ||
| 005 | 20220814071637.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180213s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000448085 |2 doi | |
| 035 | |a (DE-627)1569773653 | ||
| 035 | |a (DE-576)499773659 | ||
| 035 | |a (DE-599)BSZ499773659 | ||
| 035 | |a (OCoLC)1340987201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Reck, Martin |d 1965- |e VerfasserIn |0 (DE-588)137678711 |0 (DE-627)594837413 |0 (DE-576)30483873X |4 aut | |
| 245 | 1 | 0 | |a Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer |b German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE) |c Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A. Socinski, Henrik Depenbrock, Victoria Soldatenkova, Jacqueline Brown, Thomas Krause, Nick Thatcher |
| 264 | 1 | |c 2 August 2016 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.02.2018 | ||
| 520 | |a Background: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N | ||
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology research and treatment |d Basel : Karger, 2014 |g 39(2016), 9, Seite 539-547 |h Online-Ressource |w (DE-627)776629611 |w (DE-600)2749752-5 |w (DE-576)400081660 |x 2296-5262 |7 nnas |a Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE) |
| 773 | 1 | 8 | |g volume:39 |g year:2016 |g number:9 |g pages:539-547 |g extent:9 |a Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000448085 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.karger.com/Article/FullText/448085 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180213 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 2 | ||
| 999 | |a KXP-PPN1569773653 |e 2998880517 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"2 August 2016","dateIssuedKey":"2016"}],"id":{"doi":["10.1159/000448085"],"eki":["1569773653"]},"person":[{"role":"aut","display":"Reck, Martin","family":"Reck","given":"Martin"},{"given":"Michael","role":"aut","display":"Thomas, Michael","family":"Thomas"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A. Socinski, Henrik Depenbrock, Victoria Soldatenkova, Jacqueline Brown, Thomas Krause, Nick Thatcher"]},"title":[{"title":"Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer","title_sort":"Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer","subtitle":"German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE)"}],"relHost":[{"language":["eng"],"pubHistory":["37.2014 -"],"disp":"Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE)Oncology research and treatment","title":[{"title":"Oncology research and treatment","title_sort":"Oncology research and treatment"}],"part":{"text":"39(2016), 9, Seite 539-547","year":"2016","pages":"539-547","issue":"9","volume":"39","extent":"9"},"id":{"zdb":["2749752-5"],"eki":["776629611"],"issn":["2296-5262"]},"origin":[{"publisher":"Karger","publisherPlace":"Basel","dateIssuedKey":"2014","dateIssuedDisp":"2014-"}],"note":["Gesehen am 15.12.2023"],"recId":"776629611","physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"physDesc":[{"extent":"9 S."}],"recId":"1569773653","note":["Gesehen am 13.02.2018"],"language":["eng"]} | ||
| SRT | |a RECKMARTINNECITUMUMA2201 | ||